Downloads
Abstract
Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide, with more than half a million new cases every year. Over half of these originate from the Asia Pacific region, where HNSCC accounts for a much greater proportion of newly diagnosed cancers. Patients with recurrent or metastatic (R/M) HNSCC have a poor prognosis, and there is no effective salvage therapy. Anti-epidermal growth factor receptor monoclonal antibodies, such as cetuximab, plus platinumfluorouracil chemotherapy improve overall survival (OS), and these regimens are now standard first-line treatments for R/M HNSCC. Taxanes and methotrexate are usually used as second-line treatments. Recent studies have examined the effect of afatinib on patients with R/M HNSCC after failure of platinumbased therapy. However, these therapies provide limited benefit, and the associated toxicities may impair patient quality of life. A more effective and less toxic therapy is needed for these patie nts. Pembrolizumab, a monoclonal antibody that targets the programmed cell death protein 1 (PD-1), was approved for the treatment of melanoma and R/M HNSCC in August 2016 and was confirmed in some clinical trials phase 3. We present a case of metastatic tonsil cancer who regressed with many chemotherapy regimens and showed a great efficacy in immunotherapy at National Cancer Hospital.
References
Fitzmaurice C, Allen C, Barber RM, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Lifeyears for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017;3:524-48.
Shaikh MH, McMillan NA, Johnson NW. HPVassociated head and neck cancers in the Asia Pacific: A critical literature review & metaanalysis. Cancer Epidemiol.
Chang PM, Hsieh YY, Chen MH, et al. Cetuximabbased therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular. J Chin Med Assoc 2010;73:292–9.
Vermorken JB, Mesia R, Rivera F, et al. Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–27.
Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40:2071–6.
Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamouscell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 2015;16:583–94.
Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamouscell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245–51.
Cohen EEW, Soulières D, Le Tourneau C et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393:156-167.
Rischub D, Harringtin KJ, Greil R, et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab as firstline therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): J Clin Oncol 2019:37(15_suppl): Abstract 6000.
| Published | 07-01-2025 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 67 (2021) | |
| Section | Case report | |
| DOI | 10.38103/jcmhch.2021.67.11 | |
| Keywords | Ung thư vảy đầu cổ tái phát di căn, pembrolizumab, miễn dịch R/M HNSCC, pembrolizumab, immunotherapy |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2021 Journal of Clinical Medicine Hue Central Hospital